This Week in Biotech Bulls & Breakthroughs (Jun 22 - Jun 28, 2026)

This week, This Week in Biotech Bulls & Breakthroughs examined the regulatory landscape shaping biotech valuations through mid-2026, focusing on how evolving FDA policies could reshape clinical development timelines and investor sentiment. The episode explored the practical implications of policy shifts for companies navigating approval pathways, highlighting the tension between accelerated review mechanisms and safety oversight that continues to define the sector's near-term trajectory.